Skip to main content

Juan Espinosa Pereiro

Juan Espinosa Pereiro, graduated in Medicine from the University of Santiago de Compostela. Specialist in Internal Medicine and Infectious Diseases at the H. U. Vall d'Hebrón, in Barcelona. He is a researcher and clinical member of the International Health Program of the Catalan Institute of Health. Collaborating researcher in the EUSAT-RCS and EU-PEARL projects. He also participates in several competitive projects within the national scope. Member of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and within them their respective mycobacteria study groups (GEIM and ESGMYC, respectively). He has participated in the publication of several scientific articles in the field of Infectious Diseases, including tuberculosis, Chagas disease and COVID-19.

Institutions of which they are part

Predoctoral researcher
Infectious Diseases
Vall Hebron Institut de Recerca
Accident and Emergency Department
General Hospital
Doctor
Infectious Diseases
Cross-departmental services
EDUCATION

2007-2013: Degree with Extraordinary Award in Medicine. Universidade de Santiago de

Compostela.

PhD candidate: “Mycobacterium tuberculosis resistance to and optimization of first line

drugs.” October 2019 to present: Universitat Autónoma de Barcelona, Barcelona, Cataluña,

Spain. Director: Adrián Sánchez-Montalvá.

Residence

May 2014 -May 2019: Internal Medicine.

Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona,

Cataluña, Spain.

Subspecialization

May 2017 to May 2019: Infectious Diseases.

Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona,

Cataluña, Spain.

Internships

November-December 2018: Tropical Diseases

Oxford University Clinical Research Unit Vietnam, Hospital for Tropical Diseases, Ho Chi

Minh City, Vietnam.

October-December 2019 and June-July 2022: Tuberculosis

Instituto de Enfermedades Respiratorias y del Ambiente (INERAM), Asunción, Paraguay.

Programa Nacional de Control de la Tuberculosis (PNCT), Asunción Paraguay.


PROFFESIONAL EXPERIENCE

Licensed Physician number 50420, in Barcelona, 2014.

May 2019 to present: Emergency Department, attending physician.

May 2019 to present: Global Health and Tropical Diseases.


RESEARCH EXPERIENCE

Competitive grants participation:

November 2019 to present: Pre-doctoral Research Fellow at EU Patient-cEntric clinical tRial

pLatform (EU-PEARL). Grant number 853966.

May 2019 to present: Pre-doctoral Research Fellow at European-Latin American TB Research

Collaboration Network (EUSAT-RCS). Grant number: 823890.

Good clinical practice certificate: until April 23rd 2023.


PUBLICATIONS

First-author:

A restrospective study on the influence of sibling’s relatedness in Bolivian patients with
chronic Chagas disease. Parasites and Vectors. 2019 12:260

MDR Tuberculosis Treatment. Medicina (Kaunas). 2022 Jan 26;58(2):188. doi: 10.3390/medicina58020188.

Co-authored:

Ulcers on psoriatic plaques in a patient with advanced Human Immunodeficiency Virus infection. Enfermedades Infecciosas y Microbiología clínica, 2017 Nov;35(9):605-606. PMID 27240445.

Mixed connective tissue disease and epitope spreading: An Historical Cohort Study. Journal of Clinical Rheumatology. 2017 Apr;23(3): 155-159. PMID 28248800.

Usefulness of FDG PET/CT in the management of tuberculosis. PLoS ONE. 2019 14 (8): e0221516

Tigecycline-associated hypofibrinogenemia in a real-world setting. International Journal of Clinical Pharmacology. 2020 Aug;42(4):1184-1189. PMID: 32504166.

Blastocystis sp. carriage and irritable bowel syndrome: is the association already established? Biology. 2021, 10, 340.

Risk of SARS-COV-2 infection in previously infected and non-infected cohorts of health workers at high risk of exposure. Journal of Clinical Medicine. 2021 April, 10, 1968.

Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. Medicina Clinica. 2021 Jun 18:S0025-7753(21)00360-2. PMID: 34544604.

Impact of the COVID-19 pandemic on tuberculosis management in Spain. International Journal of Infectious Diseases. 2021 Jul;108:300-305. PMID: 33930543. Imported cystic echinococcosis in Spain: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021 Oct 1;115(10):1184-1189. PMID: 33631003.

Other publications

Guía práctica de actuación en epidemias de COVID-19 en residencias para personas mayores. [Practical actuation guideline for COVID-19 epidemics in nursing facilities]. Sociedad Española de Medicina de Familia y Comunitaria. Enero 2021.

Projects

EU Patient- cEntric clinicAl tRial pLatform - EU PEARL.

IP: Joan Genescà Ferrer
Collaborators: Santiago Pérez Hoyos, Anna Sanjuan Viaplana, María De Valles Silvosa, Sarai Rodríguez Navarro, Xavier Cañas Perea, Juan Espinosa Pereiro, Núria Gavaldà Batalla, Juan Manuel Pericàs Pulido, José Antonio Ramos Quiroga, Israel Molina Romero, Alex Sánchez Pla, Inmaculada Fuentes Camps, Elena de Sena Fernández, Esther Arevalo Andres, Susana Graciela Kalko Witruk, Adrián Sánchez Montalvá, Pol Ibañez Jimenez, Olga Sánchez- Maroto Carrizo, Gara Arteaga Henriquez, Jesus Manuel Rivera Esteban, Gabriela Perez Fuentes Ruiz, Federica Righi , Sandra Patricia de Almeida Duarte, Maria Fernanda Barroso de Sousa, Sandra Aixut Mayordomo
Funding agency: The Innovative Medicines Initiative
Funding: 1987375
Reference: EU-PEARL_H2020_IMI2-2018
Duration: 01/11/2019 - 30/04/2023

European-Latin American TB Research Collaboration Network

IP: Adrián Sánchez Montalvá
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Juan Espinosa Pereiro
Funding agency: EUROPEAN COMMISSION
Funding: 172200
Reference: EUSAT-RCS_H2020MSCA-RISE2018
Duration: 04/04/2019 - 31/03/2024

Influence of phratry in Chaga's disease: chasing the genetic basis. Influencia de la fratría en la enfermedad de Chagas: persiguiendo las bases genéticas.

IP: Juan Espinosa Pereiro
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)331/2017
Duration: -

Related news

El treball, publicat a The Lancet, ha estudiat pacients de Barcelona i Madrid i mostra que el contacte directe és la principal via de transmissió de la infecció.

HIV infected cells expressing the CD32 molecule are more resistant to the action of the natural killer cells of the immune system, which are key in the fight against viral infections.

Entre els projectes més rellevants en Covid-19 destaca la participació del VHIR en assaigs clínics per provar l’eficàcia i seguretat de vacunes com ara Janssen, Pfizer-BioNTech en el col·lectiu d’embarassades, i Hipra.

Related professionals

Maria Azucena Melgarejo Sanabria

Maria Azucena Melgarejo Sanabria

Administration and Management
Infectious Diseases
Read more
David Perea Pérez

David Perea Pérez

Predoctoral researcher
Infectious Diseases
Read more
Ibai Los Arcos Bertiz

Ibai Los Arcos Bertiz

Predoctoral researcher
Infectious Diseases
Read more
Oscar Len Abad

Oscar Len Abad

Infectious Diseases
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.